Back to News
Dec 26, 2025 12:10 PM

Johnson & Johnson Halts Atopic Dermatitis Study After Interim Analysis Miss

On Friday, Johnson & Johnson (NYSE:JNJ) shared the planned interim analysis from Phase 2b DUPLEX-AD proof-of-concept study of JNJ-95475939 for moderate to severe atopic dermatitis (AD).

Atopic dermatitis or eczema is a chronic skin condition causing dry, intensely itchy, inflamed, red (or darker/brown/grey on darker skin), and cracked skin.

The results of a planned interim analysis met prespecified criteria for early termination of the study, as they did not meet the high-bar efficacy. JNJ-5939 ...